Mark A. Weinberg
Keine laufenden Positionen mehr
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Robin J. McGarry | M | - |
Astellas Pharma Global Development, Inc.
 Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Global Development, Inc. provides business services. The company is headquartered in Deerfield, IL. | 11 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Timothy Boris | M | 55 |
RestorGenex Corp.
 RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 4 Jahre |
| David Sherris | M | 71 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
| Philip Donenberg | M | 63 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
| Isaac Blech | M | 73 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 3 Jahre |
| Sol Barer | M | 76 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 3 Jahre |
| Rex Bright | M | 84 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
| Nelson K. Stacks | M | 53 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| David G. Kalergis | M | 75 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| John L. Gainer | M | 85 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Stephen Simes | M | 72 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
| Yael Schwartz | M | 75 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 1 Jahre |
| Steven Ryder | M | 73 |
Astellas Pharma Global Development, Inc.
Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Global Development, Inc. provides business services. The company is headquartered in Deerfield, IL. | 5 Jahre |
| Frank Perabo | M | 59 |
Astellas Pharma Global Development, Inc.
Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Global Development, Inc. provides business services. The company is headquartered in Deerfield, IL. | 3 Jahre |
| Jeannette A. Barrett | M | - |
Astellas Pharma Global Development, Inc.
Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Global Development, Inc. provides business services. The company is headquartered in Deerfield, IL. | 1 Jahre |
| Sukumar Nagendran | M | 58 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
| Thomas Byrne | M | 67 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Sef P. Kurstjens | M | 60 |
Astellas Pharma Global Development, Inc.
Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Global Development, Inc. provides business services. The company is headquartered in Deerfield, IL. | 5 Jahre |
| David R. Jones | M | 60 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Robert W. Adams | M | 73 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Mark T. Giles | M | 69 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Alan Levin | M | 62 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Stephen Eck | M | 69 |
Astellas Pharma Global Development, Inc.
Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Global Development, Inc. provides business services. The company is headquartered in Deerfield, IL. | 6 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 23 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Mark A. Weinberg
- Persönliches Netzwerk
